XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net income $ 27,465 $ 26,614
Reconciliations of net income to net cash used in operating activities:    
Net cash used in operating activities (60,304) (78,861)
Depreciation and amortization 3,967 3,512
Non-cash lease expense 5,937 5,394
Investment amortization and losses recognized 1,053 343
Deferred Income taxes (1) 3,890
Share-based compensation 3,874 2,284
Changes in certain operating assets and liabilities:    
Trade accounts receivable (121,787) (48,801)
Income taxes 4,753 (405)
Prepaid expenses and other (7,457) 1,036
Accounts payable (263) 454
Accrued payroll, payroll taxes and related benefits 100,792 32,554
Other accrued liabilities 835 (2,698)
Workers' compensation claims liabilities (60,230) (93,097)
Safety incentives liability (13,464) (4,596)
Operating lease liabilities (5,773) (5,215)
Other assets and liabilities, net (5) (130)
Cash flows from investing activities:    
Purchase of property, equipment and software (5,016) (6,936)
Purchase of investments (56,775) (50,329)
Proceeds from sales and maturities of investments 72,130 46,791
Purchase of restricted investments (253,778) (32,508)
Proceeds from sales and maturities of restricted investments 110,131 45,160
Net cash (used in) provided by investing activities (133,308) 2,178
Cash flows from financing activities:    
Proceeds from credit-line borrowings 2,718  
Payments on credit-line borrowings (2,718)  
Payments on long-term debt (166) (165)
Repurchase of common stock (10,775) (2,987)
Common stock repurchased on vesting of stock awards (1,404) (1,416)
Dividends paid (6,818) (6,826)
Proceeds from exercise of stock options 1,156 3,014
Net cash used in financing activities (18,007) (8,380)
Net decrease in cash, cash equivalents and restricted cash (211,619) (85,063)
Cash, cash equivalents and restricted cash, beginning of period 233,837 273,341
Cash, cash equivalents and restricted cash, end of period $ 22,218 $ 188,278